论文部分内容阅读
目的探究前列地尔联合贝那普利对糖尿病肾病患者蛋白尿的影响。方法选取2014年8月~2015年3月我院收治的DN患者158例,随机分为对照组和研究组,各79例。对照组口服贝那普利片;研究组口服贝那普利片+静脉滴注前列地尔,治疗2个月。比较两组患者治疗前后24 h尿蛋白含量及尿微蛋白排泄率及疗效。结果经过两个月的治疗,两组患者尿蛋白含量及尿微蛋白排泄率都有明显降低,且治疗后研究组的两指标数值明显低于对照组;研究组的总有效率也明显高于对照组(P<0.05)。结论前列地尔+贝那普利联合治疗能明显减少患者蛋白尿,有效率高,具有临床推广价值。
Objective To investigate the effect of alprostadil combined with benazepril on proteinuria in patients with diabetic nephropathy. Methods A total of 158 DN patients admitted to our hospital from August 2014 to March 2015 were randomly divided into control group and study group, with 79 cases in each group. Control group oral benazepril tablets; study group oral benazepril tablets + intravenous alprostadil for 2 months. The urinary protein and urinary protein excretion rate and therapeutic effect of 24 h before and after treatment were compared between the two groups. Results After two months of treatment, urinary protein and urinary microalbumin excretion were significantly decreased in both groups, and the two indexes in the study group were significantly lower than those in the control group after treatment. The total effective rate in the study group was also significantly higher than that in the control group Control group (P <0.05). Conclusion The combination of alprostadil and benazepril can significantly reduce proteinuria in patients with high efficiency and clinical value.